Follow the BridgeBio Oncology Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €736m. The latest transaction was disclosed on 6 July 2026 (Retenue fiscale). Among the most active insiders: Chen Bihua. All data is openly available.
16
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BridgeBio Oncology Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$24.90.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
BridgeBio Oncology Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for patients with cancer. It specializes in targeted therapies and genetics-based approaches.